Abstract
Human plasmacytoid dendritic cells (pDC) are crucial for the modulation of adaptive immune responses in the course of neoplastic, viral and autoimmune diseases. In several of these disorders deregulated pDC-derived interferon-α (IFN-α), a key cytokine produced by pDC, plays a central role. Apart from IFN-α, pDC can produce a variety of other mediators, which are involved in immunological cross-talk. The most recently discovered are the cytotoxic serine protease granzyme B (GrB) and indoleamine 2,3-dioxygenase, which have been described to be involved in the suppression of effector T cell responses. Here we review the regulation of pDC function by a variety of immunomodulatory agents, which may be developed as future candidates for the therapy of a variety of diseases. Moreover, we introduce the novel concept of enhancing immune responses after vaccination in poor responders by increasing pDC-derived IFN-α and simultaneously inhibiting pDC-derived GrB secretion. Finally we discuss potential approaches to abrogate pDC-mediated tolerance induction against tumors and viral infections.
Keywords: pDC, IFN-α, TNF-α, granzyme B, TRAIL, IDO, HMGB1, IL-6, IL-12, IP-10, Interleukin, Vasoactive intestinal peptide
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Approaches to the Pharmacological Modulation of Plasmacytoid Dendritic Cells
Volume: 11 Issue: 2
Author(s): Dorit Fabricius and Bernd Jahrsdorfer
Affiliation:
Keywords: pDC, IFN-α, TNF-α, granzyme B, TRAIL, IDO, HMGB1, IL-6, IL-12, IP-10, Interleukin, Vasoactive intestinal peptide
Abstract: Human plasmacytoid dendritic cells (pDC) are crucial for the modulation of adaptive immune responses in the course of neoplastic, viral and autoimmune diseases. In several of these disorders deregulated pDC-derived interferon-α (IFN-α), a key cytokine produced by pDC, plays a central role. Apart from IFN-α, pDC can produce a variety of other mediators, which are involved in immunological cross-talk. The most recently discovered are the cytotoxic serine protease granzyme B (GrB) and indoleamine 2,3-dioxygenase, which have been described to be involved in the suppression of effector T cell responses. Here we review the regulation of pDC function by a variety of immunomodulatory agents, which may be developed as future candidates for the therapy of a variety of diseases. Moreover, we introduce the novel concept of enhancing immune responses after vaccination in poor responders by increasing pDC-derived IFN-α and simultaneously inhibiting pDC-derived GrB secretion. Finally we discuss potential approaches to abrogate pDC-mediated tolerance induction against tumors and viral infections.
Export Options
About this article
Cite this article as:
Fabricius Dorit and Jahrsdorfer Bernd, Approaches to the Pharmacological Modulation of Plasmacytoid Dendritic Cells, Endocrine, Metabolic & Immune Disorders - Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187153011795564205
DOI https://dx.doi.org/10.2174/187153011795564205 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthetic Sphingosine 1-Phosphate Receptor Modulators - Opportunities and Potential Pitfalls
Current Topics in Medicinal Chemistry Mucosal Immunity - Basic Principles, Ontogeny, Cystic Fibrosis and Mucosal Vaccination
Current Drug Targets - Immune, Endocrine & Metabolic Disorders CCR2 Antagonists
Current Topics in Medicinal Chemistry Biological Therapies of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Immune Aging and Autoimmune Diseases in Children
Current Immunology Reviews (Discontinued) Unique Phenotypes and Functions of Follicular Helper T Cells and Regulatory T Cells in Sjögren’s Syndrome
Current Rheumatology Reviews KIR Molecules: Recent Patents of Interest for the Diagnosis and Treatment of Several Autoimmune Diseases, Chronic Inflammation, and B-cell Malignancies
Recent Patents on DNA & Gene Sequences Case-control Association Study of Autoimmunity Associated Variants in PDCD1 and Juvenile Idiopathic Arthritis
Current Rheumatology Reviews Novel Topical Nanocarriers for Treatment of Psoriasis: An Overview
Current Pharmaceutical Design Nucleic Acid Enzymes as a Novel Generation of Anti-gene Agents
Current Molecular Medicine Lipids at the Cross-road of Autoimmunity in Multiple Sclerosis
Current Medicinal Chemistry Molecular Characteristics of Autoimmune Pancreatitis
Current Pharmaceutical Design Altered Peptide Ligand Antagonism: From Immune Evasion to Immunotherapy
Drug Design Reviews - Online (Discontinued) The Impact of Post-Genomics Approaches in Neurodegenerative Demyelinating Diseases: The Case of Guillain-Barré Syndrome
Current Medicinal Chemistry Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) Vaccination and Induction of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Celastrol and Terpenes as Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry Analogs of the Sea Anemone Potassium Channel Blocker ShK for the Treatment of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) From Cannabis to Endocannabinoids in Multiple Sclerosis: A Paradigm of Central Nervous System Autoimmune Diseases
Current Drug Targets - CNS & Neurological Disorders